September is Blood Cancer Awareness Month
Show your support and be a part of Blood Cancer Awareness Month
We're supporting Blood Cancer Awareness Month by providing these resource links and a downloadable blood cancer awareness ribbon. Download the red awareness ribbon and use it in your email signature, on your Facebook page, Twitter or other social media account during September.
Light The Night Walk® is a fundraising campaign of The Leukemia & Lymphoma Society. Light The Night Walk funds research to find cures and ensure access to treatments for all blood cancer patients. Coming together for a common goal, friends, families and co-workers form fundraising walk teams. Culminating in inspirational and memorable evening walks every fall, participants in nearly 200 communities across North America join together carrying illuminated lanterns to take steps to end cancer.
At Seattle Genetics, we're excited to show our passion for helping patients by forming teams at Light The Night Walks across the U.S. Will you join us?
Throughout the month of September, buildings and iconic landmarks around the world Light it Red for Lymphoma to not only raise awareness of the disease, but to help provide hope to all those touched by lymphoma. Use #LightItRed in your social media posts showing your visit to a Light It Red site.
On September 15, the global lymphoma community stands together to raise awareness of lymphomas, to tell the world that lymphoma is a cancer that can’t be ignored.
We're wearing red in honor of Blood Cancer Awareness Month, and a brighter future for all touched by lymphoma.
The Lymphoma Research Foundation is committed to providing members of the lymphoma community with accurate, up-to-date information about the diagnosis and treatment of the disease with in-person educational conferences all around the U.S. The North American Educational Forum takes place in Brooklyn October 20-22.
About Blood Cancer
About half of the blood cancers that occur are lymphomas, or cancers of the lymphatic system.
Hodgkin lymphoma is one of two major categories of lymphoma. It is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. The American Cancer Society estimates that more than 8,200 people will be diagnosed with Hodgkin lymphoma in the United States during 2017.
Non-Hodgkin lymphoma is the second major category of lymphoma and represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are a type of white blood cell that are responsible for defending the body against infection. Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for up to 30 percent of newly diagnosed cases in the United States. According to the American Cancer Society, more than 72,000 people are expected to be diagnosed with non-Hodgkin lymphoma in the United States during 2017.
Leukemia is a type of cancer that affects the blood and bone marrow, the spongy center of bones where blood cells are formed. The disease develops when blood cells produced in the bone marrow grow out of control. The four most common types of leukemia are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
Acute myeloid leukemia is a type of bone marrow cancer. The American Cancer Society estimates that more than 21,000 cases of AML will be diagnosed in the United States during 2017, and more than 10,500 people will die from the disease.
Multiple myeloma is a rare and aggressive cancer that forms in white blood cells called plasma cells. Cancerous plasma cells can crowd out healthy blood cells, impair bone strength and weaken the immune system. Despite recent medical advances, multiple myeloma remains an incurable disease in which patients eventually progress and die. After lymphoma and leukemia, multiple myeloma is the third most common blood cancer in the US. The American Cancer Society estimates that more than 30,000 new cases will be diagnosed in 2017.